NCT01942785View on ClinicalTrials.gov

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2014

Conditions
Major Depressive DisorderIrritability
Interventions
DRUG

Brexpiprazole

2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.

Trial Locations (15)

Unknown

US015, Tucson

US019, Glendale

US016, Oakland

US014, San Diego

US011, Denver

US018, Hallandale

US009, Jacksonville

US005, Orlando

US006, Gaithersburg

US012, Weymouth

US003, Jamaica

US001, Dayton

US007, Portland

US004, Memphis

US002, Seattle

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT01942785 - Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy | Biotech Hunter | Biotech Hunter